Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 2 Interventional Results available

Revefenacin in Acute Respiratory Insufficiency in COPD

NCT04315558
View directory record Official record
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Intensive Discharge Intervention in Diabetes

NCT02122926
View directory record Official record
Conditions
Type II Diabetes, Cardiovascular Disease
Interventions
Intensive discharge intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2014 · Synced Oct 25, 2026, 2:07 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Intravenous Fluids in Pediatric Migraine

NCT06182098
View directory record Official record
Conditions
Migraine, Migraine in Children
Interventions
1/2 maintenance fluids, Ketorolac, Diphenhydramine, Prochlorperazine, bolus
Other · Drug
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 21 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT02905006
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
Fremont, California • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 25, 2026, 2:07 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome

NCT05271487
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Multi-Step Botanical Skin Care Regimen
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
15 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

NCT02453321
View directory record Official record
Conditions
Pain, Postoperative, Total Knee Arthroplasty (TKA)
Interventions
Continuous Femoral Nerve Block, Nerve Block, Continuous Adductor Canal, Continuous Sciatic Nerve Block, Bupivacaine
Procedure · Drug
Lead sponsor
Kevin King, DO
Other
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ZIKA Vaccine in Naive Subjects

NCT02952833
View directory record Official record
Conditions
Zika Virus Infection
Interventions
Saline, Zika Virus Purified Inactivated Vaccine (ZPIV)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Influence of Patient Sex on Pain Control and Multimodal Analgesia in Total Knee Arthroplasty

NCT04471233
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Postoperative
Interventions
Multimodal analgesia including pregabalin, Multimodal analgesia not including pregabalin
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

NCT00574548
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
6
States / cities
Chandler, Arizona • Pembroke Pines, Florida • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 25, 2026, 2:07 AM EDT
Terminated Not applicable Interventional

Knee Isometric Program (KIP) Home Exercise Programs (HEP) Physical Therapy (PT) Study

NCT06536426
View directory record Official record
Conditions
Anterior Knee Pain Syndrome
Interventions
Knee Isometric Program (KIP)
Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

NCT03000348
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cysteamine, Placebo Oral Capsule
Drug
Lead sponsor
NovaBiotics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Tucson, Arizona • San Francisco, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Not applicable Interventional Results available

A Study to Determine the Effects of Adding an Experimental Device With Mouthrinse to Oral Care Regimen

NCT01419626
View directory record Official record
Conditions
Gingivitis
Interventions
Interdental cleaning device with water, Interdental cleaning device with essential-oil mouthrinse
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Reducing the Weight of Overweight Schizophrenia Patients

NCT00158366
View directory record Official record
Conditions
Schizophrenia, Obesity
Interventions
Behavioral training, Social skills training, Behavioral training booster sessions
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 60 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

ICE-T Pain Regimen for Total Laparoscopic Hysterectomy

NCT03987022
View directory record Official record
Conditions
Opioid Substitution Treatment
Interventions
Ketorolac, Opioids, Ice Packs, Tylenol, Motrin, Dilaudid Injectable Product, Percocet 5Mg-325Mg Tablet
Drug · Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional

Nursing Intervention for HIV Regime Adherence Among People With Serious Mental Illness (SMI)

NCT00264823
View directory record Official record
Conditions
HIV, Mental Illness
Interventions
Use of Memory Aids to take medications
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2008 · Synced Oct 25, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

NCT01688882
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease

NCT02760433
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab, Placebo
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Covina, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis

NCT05223868
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
JNJ-77242113, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
21
States / cities
Phoenix, Arizona • Sacramento, California • Ocala, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 25, 2026, 2:07 AM EDT
Recruiting No phase listed Observational

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

NCT07028489
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Monterey, California • Torrance, California • Walnut Creek, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 2:07 AM EDT
Withdrawn Phase 2 Interventional

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

NCT04350450
View directory record Official record
Conditions
COVID, Coronavirus, COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex

NCT04677543
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
ALIS, Azithromycin, Ethambutol, ELC
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
27
States / cities
Birmingham, Alabama • Fresno, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 25, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

NCT04223778
View directory record Official record
Conditions
HIV Infection
Interventions
DOR/ISL, ART
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
15
States / cities
Washington D.C., District of Columbia • Ft. Pierce, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 2:07 AM EDT